Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure

International Centre for Circulatory Health, St Mary's Hospital and Imperial College, London, UK.
Heart (British Cardiac Society) (Impact Factor: 5.6). 01/2009; 95(1):56-62. DOI: 10.1136/hrt.2007.134973
Source: PubMed


Although higher blood pressures are generally recognised to be an adverse prognostic marker in risk assessment of cardiology patients, its relationship to risk in chronic heart failure (CHF) may be different.
To examine systematically published reports on the relationship between blood pressure and mortality in CHF.
Medline and Embase were used to identify studies that gave a hazard or relative risk ratio for systolic blood pressure in a stable population with CHF. Included studies were analysed to obtain a unified hazard ratio and quantify the degree of confidence.
10 studies met the inclusion criteria, giving a total population of 8088, with 29 222 person-years of follow-up. All studies showed that a higher systolic blood pressure (SBP) was a favourable prognostic marker in CHF, in contrast to the general population where it is an indicator of poorer prognosis. The decrease in mortality rates associated with a 10 mm Hg higher SBP was 13.0% (95% CI 10.6% to 15.4%) in the heart failure population. This was not related to aetiology, ACE inhibitor or beta blocker use.
SBP is an easily measured, continuous variable that has a remarkably consistent relationship with mortality within the CHF population. The potential of this simple variable in outpatient assessment of patients with CHF should not be neglected. One possible application of this information is in the optimisation of cardiac resynchronisation devices.

Download full-text


Available from: Justin Davies, Jan 26, 2015
  • Source
    • "Moreover, a fall in perfusion pressure may have adverse consequences in heart failure, including activation of the renin–angiotensin and sympathetic nervous systems, leading to sodium retention and further derangement in blood flow distribution . A low blood pressure is a bad prognostic sign in heart failure (Raphael et al., 2009). ERAs have worsened arterial oxygen saturation Table 1 Clinical trials investigating the effects of ERA therapy on symptoms, ventricular remodeling, or clinical outcome in patients with heart failure. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the early 1990s, within three years of cloning of endothelin receptors, orally active endothelin receptor antagonists (ERAs) were tested in humans and the first clinical trial of ERA therapy in humans was published in 1995. ERAs were subsequently tested in clinical trials involving heart failure, pulmonary arterial hypertension, resistant arterial hypertension, stroke/subarachnoid hemorrhage and various forms of cancer. The results of most of these trials - except those for pulmonary arterial hypertension and scleroderma-related digital ulcers - were either negative or neutral. Problems with study design, patient selection, drug toxicity, and drug dosing have been used to explain or excuse failures. Currently, a number of pharmaceutical companies who had developed ERAs as drug candidates have discontinued clinical trials or further drug development. Given the problems with using ERAs in clinical medicine, at the Twelfth International Conference on Endothelin in Cambridge, UK, a panel discussion was held by clinicians actively involved in clinical development of ERA therapy in renal disease, systemic and pulmonary arterial hypertension, heart failure, and cancer. This article provides summaries from the panel discussion as well as personal perspectives of the panelists on how to proceed with further clinical testing of ERAs and guidance for researchers and decision makers in clinical drug development on where future research efforts might best be focused.
    Full-text · Article · Aug 2012 · Life sciences
  • Source
    • "The pressure measured is the main criterion for diagnosis of acute heart failure (vasoactive shock). In recent years the importance of systolic pressure as a predictor of mortality in patients with acute and chronic [25] forms of heart failure has been recalled. Low pressure in patients suffering from chronic forms of heart failure is recognized as a positive prognostic factor of mortality. "

    Full-text · Chapter · Aug 2011
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RESUMO Vários estudos têm demonstrado que o tratamento da hi- pertensão sistólica é associado com significativas reduções da morbidade e mortalidade cardiovasculares. Enquanto a redução do risco de acidente vascular encefálico, de todos os eventos cardíacos fatais e não fatais e de insuficiência cardíaca, está bem estabelecida, a influência do tratamen - to no risco de demência deve ser mais bem conhecida. A primeira opção de droga ou começar o tratamento com a associação de dois medicamentos é uma escolha funda- mentada nas características dos pacientes e nas doenças associadas. Parece seguro reduzir a pressão sistólica para atingir a meta do tratamento enquanto a pressão diastólica for igual a 55 mmHg ou maior. Quando o paciente possuir doença coronária, o limite é a diastólica de 70 mmHg, para evitar o aumento do risco de eventos cardiovasculares. PALAVRAS-CHAVE ABSTRACT Many clinical trials have demonstrated that the treatment of systolic hypertension is associated with significant decrease in cardiovascular morbidity and mortality. While the reduction of the stroke, of all fatal and non-fatal cardiovascular events and the cardiac failure risk are well established, the treatment influence on dementia risk should be better elucidated. The first drug option or to start the treatment using an association of two medications is a choice based in patient characteristics and associated diseases. It looks like safe to reduce the systolic blood pressure to get the treatment goal until there is a diastolic blood pressure of 55 mmHg or higher. When the patient has a coronary disease, the limit is a diastolic blood pressure of 70 mmHg, in order to avoid increasing the risk of cardiovascular events.
    Full-text · Article ·
Show more